ClinicalTrials.gg
CompletedNCT05383352SIRACUSAUpdated Apr 30, 2025

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

A Phase 1 interventional study of Irinotecan liposome injection and Irinotecan liposome injection in Metastatic Pancreatic Adenocarcinoma, sponsored by Ipsen. Completed at 36 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Ipsen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas.

Adult participants with metastatic pancreatic adenocarcinoma will receive Test Product (TP) and Reference Product (RP) Onivyde in line with its approved indication. The order in which they receive them depends on the group to which they are randomly assigned, this will be referred to as the crossover phase.

The average study duration for each participant until end of crossover phase is estimated to be approximately 3 months. After completion of the crossover phase, participants who in the opinion of the investigator will benefit from the treatment will be offered to enter the extension phase where they will receive the commercial Onivyde (RP) until disease progression, withdrawal, unacceptable toxicity or death. Metastatic pancreatic adenocarcinoma is a cancer that has spread (metastasized) beyond the area of the pancreas to other organs of the body.

Onivyde is approved for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with 5-fluorouracil (5-FU) and leucovorin (LV).

02

Conditions studied

  • Metastatic Pancreatic Adenocarcinoma
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age at the time of signing the .
  • Participants who have histological or confirmed adenocarcinoma of the pancreas.
  • Participants with an initial diagnosis of progressive disease
  • Participants with a confirmed diagnosis of metastatic adenocarcinoma of the pancreas with disease progression following gemcitabine-based therapy.
  • (ECOG) performance status of ≤1
  • Adequate haematological parameters
  • Adequate hepatic function
  • Adequate renal function
  • Adequate coagulation
  • No abnormalities in urinalysis results
  • (ECG) without any clinically significant findings
  • Participants known to be infected with controlled (HIV)
  • Male and female participants: use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria :

  • Have only localised advanced disease.
  • History of any second in the last 2 years.
  • Known history of central nervous system
  • gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, diarrhoea >Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction.
  • Concurrent illnesses that would be a relative to trial participation such as active cardiac or liver disease
  • Active infection or an unexplained fever >38.5°C on the first scheduled day of dosing
  • Neuroendocrine tumour (carcinoid, islet cell) or acinar pancreatic carcinoma
  • History of interstitial lung disease, history of slowly progressive dyspnoea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary pneumonitis or multiple allergies.
  • Exposure to a non-liposomal irinotecan or SN-38 based regimen within 4 weeks prior to randomisation, or exposure to Onivyde or other irinotecan based liposomal products within 6 weeks prior to randomisation
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to randomisation
  • Participants who have received a within 4 weeks prior to randomisation.
  • Use of strong inhibitors or inducers, or strong inhibitors of UGT1A1.
  • therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to study intervention on Cycle 1 Day 1
  • Known low or absent dihydropyrimidine dehydrogenase (DPD) activity.
  • Homozygous for the UGT1A1*28 allele.
  • Known hypersensitivity to any of the components of Onivyde injection, other liposomal products, or any components of 5-FU, or LV
  • Presence of any contraindications outlined in the Contraindications or Warnings and Precautions sections of the IB for Onivyde, or in the prescribing information for 5-FU or LV.
  • Participants who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening
  • Any other medical or social condition deemed by the investigator to be likely to interfere with a participant's ability to sign , cooperate and participate in the study, or interfere with the interpretation of the results
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Sequence RT: Reference Product followed by Test Product

    Cycle 1 (Crossover Phase) Day 1: One dose Onivyde® Reference product + 5-FU/LV. Cycle 1 (Crossover Phase) Day 15: One dose Onivyde Test product + 5-FU/LV Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV

    Drug: Irinotecan liposome injection · Drug: Folinic Acid · Drug: 5-Fluorouracil

  • Experimental
    Sequence TR: Test Product followed by Reference Product

    Cycle 1 (Crossover Phase) Day 1: One dose Onivyde Test product + 5-FU/LV. Cycle 1 (Crossover Phase) Day 15: One dose Onivyde® Reference product + 5-FU/LV. Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV.

    Drug: Irinotecan liposome injection · Drug: Folinic Acid · Drug: 5-Fluorouracil

Interventions

  • Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)

    Also known as: Onivyde® Reference product

  • Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)

    Also known as: Onivyde Test product

  • Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)

    Also known as: Onivyde Test product

  • Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)

    Also known as: Onivyde® Reference product

  • LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle

    Also known as: Leucovorin (LV)

  • 5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle

    Also known as: 5-FU

06

What researchers measure

Primary outcomes

  1. Maximum (peak) plasma drug concentration (Cmax) of encapsulated irinotecan for Test relative to and Reference product

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  2. Area under the plasma concentration-time curve from time 0 to time t (AUC(0-t) of encapsulated irinotecan for Test relative to Reference product

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC(0-∞) of encapsulated irinotecan for Test relative to Reference product

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

Secondary outcomes

  1. Maximum (peak) plasma drug concentration (Cmax) of total irinotecan for Test relative to Reference product

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  2. Area under the plasma concentration-time curve from time 0 to time t (AUC(0-t)) of total irinotecan for Test relative to Reference product

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC(0-∞)) of total irinotecan for Test relative to Reference product

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  4. Time to maximum plasma concentration (Tmax) of encapsulated and total irinotecan over 15-days for each Test and Reference products

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  5. Apparent clearance of drug from plasma (CL) of encapsulated and total irinotecan for Test and Reference products

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  6. Apparent volume of distribution (VZ) of encapsulated and total irinotecan for Test and Reference products

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  7. Terminal half-life (t1/2) of encapsulated and total irinotecan for Test and Reference products

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  8. Apparent terminal elimination rate constant (λZ) of encapsulated and total irinotecan for Test and Reference products

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  9. Percentage of participants with treatment-emergent adverse events (TEAEs) treatment-related leading to discontinuations, or to death

    Including treatment-emergent serious adverse events

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

  10. Percentage of participants with clinically significant abnormal values

    It includes clinically significant abnormal laboratory results, physical examination findings, Electrocardiogram (ECG) and vital signs

    Time frame: Crossover Phase (From Cycle 1 Day 1 to Day 28 and Cycle 1 Day 29 (pre-dose))

07

Study locations

36 sites
  • Flinders Medical Centre
    Bedford Park, Australia
  • Peninsula and Southeast Oncology - Frankston Private Hospital
    Frankston, Australia
  • Institut BERGONIE Centre de Lutte Contre le Cancer
    Bordeaux, France
  • Centre GEORGES FRANÇOIS LECLERC
    Dijon, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite Cedex, 69495, France
  • Chu La Miletrie
    Poitiers, France
  • Centre PAUL STRAUSS
    Strasbourg, France
  • University Hospital Dresden
    Dresden, Germany
  • Asklepios Klinik Altona
    Hamburg, 22763, Germany
  • Caritasklinikum Saarbruecken St Theresia
    Saarbrücken, 66113, Germany
  • Mav Korhaz Es Kozponti Rendelointezet
    Budapest, Hungary
  • Semmelweis Egyetem
    Budapest, Hungary
  • Clinexpert Kft Fázis I. Vizsgálóhely
    Gyöngyös, Hungary
  • AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna
    Bologna, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
    Meldola, Italy
  • Instituto Europeo di Oncologia
    Milano, Italy
  • Azienda Ospedaliero Universitaria Modena
    Modena, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I
    Torrette, Italy
  • Ospedale Borgo Roma
    Verona, Italy
  • Hospital Senhora Da Oliveira - Hso-Epe
    Guimarães, Portugal
  • Centro Hospitalar Lisboa Norte - Hospital de Santa Maria
    Lisboa, Portugal
  • Fundacao Champalimaud
    Lisboa, Portugal
  • Chuac Hospital Teresa Herrera
    A Coruña, Spain
  • Hospital Universitario de Badajoz
    Badajoz, Spain
  • Hospital Universitario Vall D Hebron
    Barcelona, Spain
  • Instituto Oncologico Dr Rosell Lor
    Barcelona, Spain
  • Hospital Universitari de Lleida Arnaud de Villanova
    Lleida, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Quiron Salud
    Madrid, 28223, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Md Anserson Cancer Center
    Madrid, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Spain
  • Complejo Hospitalario Universitario de Santiago de Compostela -Chus
    Santiago De Compostela, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in May 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2022
First posted
May 20, 2022
StartActual
May 30, 2022
Primary completionActual
May 27, 2024
CompletionActual
Apr 15, 2025
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05383352
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
May 20, 2022
Start date
May 30, 2022
Primary completion
May 27, 2024
Completion
Apr 15, 2025
Last update
Apr 30, 2025

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion